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Is There a Critical Target Gene for the First
Step in Carcinogenesis?
by Ann R. Kennedy*
Our work has suggested that a high-frequency event is involved in the initiation phase of malignant
transformation in vitro; a later, mutationlike event appears to be involved in the later stages of transfor-
mation. There may be nospecific "targetgene"whichdirectly interacts withcarcinogens. It is hypothesized
that nonspecific types of DNA damage are involved in the induction of an ongoing process we know as
carcinogenesis. Several genes could be involved in maintaining this process. Our recent results suggest
that c-myc and c-fos could be involved in the early stages of carcinogenesis, as they are affected by
anticarcinogenic protease inhibitors in a manner that corresponds to the way in which protease inhibitors
suppress malignant transformation.
Nature of the Initiating Event in
Carcinogenesis
Our previous work has suggested that a high-fre-
quency event is involved in the induction of radiation-
induced transformation in vitro (1-8). The work of sev-
eral other investigators has now suggested that a sim-
ilar high-frequency initiating event occurs in carcino-
genesis in both in vitro and in vivo systems, with many
different types of DNA-damaging agents initiating the
carcinogenic process, as has been reviewed elsewhere
(7-11).
Given the high-frequency nature of the initiating
event in carcinogenesis, it is unlikely to be a specific
locus mutation, as studies ofmutation frequencies have
shownthemto occuratorders ofmagnitudebelowthose
observed for malignant transformation. The initiating
event does not behave like a mutation, as it appears to
be a reversible phenomenon. We have observed that
certain protease inhibitors, which are highly effective
in their ability to suppress malignant transformation in
vitro (12) and in vivo (13), are capable ofreversing ini-
tiation (14). There ismuchevidence frominvivo studies
that lesions thought to represent "initiated" or "pre-
malignant" cells are capable ofreverting totheirnormal
state. For example, Terzaghi-Howe (15) observed that
contact with normal tracheal epithelium could revert
initiated "pre-neoplastic" tracheal epithelial cells to a
normal condition. It is well known that "premalignant"
lesions invivo, such as squamous metaplasia, dysplasia,
etc., are readily reversible in nature.
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The nature of the high-frequency initiating event is
unknown. Several radiation/carcinogen-induced pro-
cesses that could be involved in carcinogenesis and are
likely explanations for our observations have been dis-
cussed elsewhere (1-8). There aremanypossibilities for
the initiating eventincarcinogenesis. Forexample, car-
cinogens such as radiation have been shown to alter
DNAmethylation patternsinawidespread fashion(16).
Methylation of DNA is thought to play an important
role in gene regulation; we have hypothesized that the
initiating event in carcinogenesis involves altered gene
expression (1-8). Another event that is induced in a
widespread fashion in a population of mammalian cells
by a number of different carcinogens (including radia-
tion) is gene amplification (17-19). It is ofinterest to us
that modifiers of carcinogenesis also affect the level of
gene amplification; for example, gene amplification can
be potentiated by tumor-promoting agents such as 12-
O-tetradecanoylphorbol-13-acetate (TPA) (19) and in-
hibited by agents that suppress carcinogenesis, such as
certain protease inhibitors known to have anticarcino-
genic activity (20). The nature ofthe initiating event in
carcinogenesis deserves much more intensive study.
Target Genes in Carcinogenesis
Severalgenesarelikelytobeinvolvedinmaintenance
of the ongoing process induced by carcinogens. Two
genes are of particular interest to us in that their
expression is affected by the anticarcinogenic protease
inhibitors in a manner which corresponds to the way in
which the protease inhibitors affect the induction of
transformation in vitro; these genes are c-myc (21-24)
and c-fos (25). Protease inhibitors affect the expression
of these genes as summarized in Table 1. As the anti-A. R. KENNEDY
Table 1. Suppression of gene expression by protease inhibitors.a
Ability ofprotease inhibitors to suppress:
c-myc expression
Nontransformed Transformed c-fos Radiation-induced
Protease inhibitor Actin expression cells cells expression transformation
Bowman-Birk ++ -+ + + + + +
Antipain + + + + + + +
Leupeptin NDb + + ND ND + +
a1-antitrypsin ND - ND
Elastatinal ND - ND ND
Soybean trypsin inhibitor ND - ND ND
aIn terms of effective molar concentrations of protease inhibitors.
bND, not determined.
carcinogenic protease inhibitors are not capable of af-
fecting c-myc expression in transformed cells but do
affect c-myc in nontransformed cells, our results sug-
gest that c-myc regulation may be ofgreat importance
in the malignant transformation ofcells, as discussed in
detail elsewhere (24).
We have hypothesized that the anticarcinogenic pro-
tease inhibitor effects on c-myc expression and malig-
nant transformation are involved in an early stage of
carcinogenesis, even though protease inhibitors can af-
fect carcinogenesis atlongtimeperiods aftercarcinogen
exposure (14). Our proposed scheme for the induction
ofmalignant transformation in vitro is shown in Figure
1.
Carcinogens such as radiation are known to induce c-
myc; we have shown that c-myc is induced in vivo by
radiation and that anticarcinogenic protease inhibitors
reduce c-myc expression to normal levels (26). It has
also been shown that c-myc expression is elevated in
radiation-induced tumors (27). As shown in Figure 1, it
is expected that anticarcinogenic protease inhibitors re-
duce c-myc expression to normal levels aftercarcinogen
exposure; this phenomenon has been shown to occur in
the irradiated mouse colon (26). It is possible that ele-
vated c-myc expression influences the level of expres-
sion of another gene-specifically, as shown in Figure
1, a gene coding for a particular protease, the Boc-Val-
Pro-Arg-MCA hydrolyzing activity, which has been
studied extensively in our laboratory (13,28-30).
The c-myc gene codes for a nuclear binding protein
and is thought to play a regulatory role in gene tran-
scription (31). Our research would suggest that there
must be persistent activation ofthe process involved in
malignant transformation. While c-myc is only tran-
siently activated by radiation (26), the Boc-Val-Pro-
Arg-MCA hydrolyzing activity is persistently activated
by carcinogen exposure (30). We have observed higher
than normal levels ofBoc-Val-Pro-Arg-MCA hydrolyz-
ing activity in normal-appearing areas of carcinogen-
treated epithelial cellsinvivo, even atlongtimeperiods
after carcinogen exposure (30). This proteolytic activity
is directly affected by the anticarcinogenic protease in-
hibitors in a manner that corresponds to the way in
which these agents suppress malignant transformation
in vitro (13,28) and in vivo (13,30). As shown in Figure
1, it is proposed that c-myc induction precedes the in-
duction of the protease (Boc-Val-Pro-Arg-MCA hydro-
lyzing activity). It is perhaps equally likely that the
orderofthesetwophenomenaisreversed, asitisknown
that proteases such as plasminogen activator induce c-
myc expression. Many other agents studied in carcin-
ogenesis research induce c-myc expression; for exam-
ple, TPAisknowntoinducec-mycgeneexpression(32).
We have hypothesized that a late event is involved
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FIGURE 1. Our hypothesized scheme for events involved in radiation transformation in vitro. Anticarcinogenic protease inhibitors have been
shown to affect both c-myc and a specific proteolytic activity (the Boc-Val-Pro-Arg-MCA hydrolyzing activity), as described in the text.
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in actually transforming a cell to the malignant state
(1-8,12). In Figure 1, we have hypothesized that the
activation of ras is involved in a late stage of carcino-
genesis. There are several ways in which an interaction
between the events we believe are related to the early
stages ofcarcinogenesis (i.e., theinductionofc-mycand
the induction of a protease such as the Boc-Val-Pro-
Arg-MCAhydrolyzingactivity) and members oftheras
gene family could occur. Cooperation between myc and
ras in the induction of transformation is well docu-
mented (33,34). The Boc-Val-Pro-Arg-MCA hydrolyz-
ing activity has characteristics that make it likely to be
involved in the processing of a growth factor like epi-
dermal growth factor (EGF) (13,28). Ifthis proteolytic
activity were involved in the processing of a growth
factor like EGF, more ofan EGF-like substance would
be present than under normal conditions. Carcinogen-
treated cells growing under the influence ofabnormally
large amounts of a growth factor would be likely to
exhibit altered growth characteristics; such altered
growth patterns are known to occur in a widespread
fashion in carcinogen-treated tissue (and are known as
premalignant changes). We propose that an additional
change occurs in these atypical areas and that it is this
later change that leads directly to malignancy; the evi-
dence for such a late step in the malignant transfor-
mation of C3H1OT1/2 cells and carcinogenesis in vivo
has been reviewed (1-8,12). We propose here that this
later change involves the activation ofras, which occurs
as a late event in several in vitro systems (e.g., 35) and
is known to be activated in many different kinds of
cancers, including those induced by radiation (36,37). It
is possible that the activation ofras is connected to the
cellular effects brought about by EGF, as it is known
that the p21 proteins of ras interact with the EGF re-
c myc gene:
Cthomosome 8
PO PI P2
Promoter
ceptor (the product of c-Ha-ras is activated by EGF)
(38). Although the Boc-Val-Pro-Arg-MCA hydrolyzing
activity we have studied has characteristics similar to
EGF binding protein (28), which is thought to be in-
volved in the processing of EGF, it is not exactly like
EGF binding protein. Thus, we have hypothesized that
a growth factor involved in the malignant transforma-
tion ofcells in the systems we have used maybe similar
to EGF.
There is some evidence to suggest that a growth fac-
tor like EGF is involved in the induction of transfor-
mation in vitro; for example, EGF is known to promote
transformation in vitro (39), and it is known that EGF
as a promoting agent can bring about an irreversible
change in cells (such as a point mutation in ras that
leads to its activation), thatis, the switch to anchorage-
independent growth (which correlates with tumori-
genicity) in promotable cells (40).
Protease Inhibitor Suppression of c-
myc Gene Expression
The mechanism by which anticarcinogenic protease
inhibitors suppress c-myc gene expression is unknown,
although many hypotheses have been presented else-
where(21-24). Apotentialmodelforc-mycgeneexpres-
sion and its regulation by a protease is shown in Figure
2. Our model proposes that a protease is capable of
destroying a regulatory protein involved in the regu-
lation of c-myc; this regulatory protein would conceiv-
ably bind to the promoter region ofthe gene, as shown
in Figure 2. Carcinogens could increase the level ofthe
protease, which would lead to decreased levels of the
regulatory protein; decreased binding ofthe regulatory
FXON ?
_0~
f XON:
{:1- :13
Exons 2 and 3 Iranslated _ myc protein
RP-bonds to promoter
region of gene
t I Prolease
Inhebilor
| Regulatory1|u-#-- Protease
| Proleeln | / roes
MOLDtL FVR RAIATION ANDU PtRT ASE BIttOR EFtFEt OUN c-mnyc EtESSbIUN
Normal regiateon
of c myc gene
Radeation
Raddaton
Antccare mc
prolease oiltors
PROTEASE LEVELS REGULATORY PROTEIN (F1P)
i On -RP bound to promoter
9 Otf RP not bound lo promoltr
43
FW destroyed by protase.
RP not bound to promoter
RP no tonbw bee destroned
by incr"s"d proles" tents.
thu RP can bind to promoter
tL Vt L Of I XPRIS&N
Of c myz:
tI
FIGURE 2. Proposed model to explainc-mycgeneexpression and itsregulationbyaprotease. It ishypothesized thatanticarcinogenic protease
inhibitors operate in our proposed model as described in the text. (1-3) Evidence in support ofproposed model: c-myc expression increases
in radiation-induced tumors in vivo protease levels increase in carcinogen-treated tissue in vivo (30), anticarcinogenic protease inhibitors
return protease levels to normal (30).
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protein to the promoterregion ofc-myc would then lead
to increased levels ofc-myc gene expression. Evidence
in support ofthis partoftheproposedmodelcomesfrom
experiments showing that: a) carcinogens induce ele-
vated levels of a protease: Boc-Val-Pro-Arg-MCA hy-
drolyzing activity (13,28); b) radiation increases c-myc
gene expression (26); and c) c-myc gene expression in-
creases in radiation-induced tumors in vivo (27).
Conceivably, anticarcinogenic protease inhibitors
could then inhibit the protease that destroys the reg-
ulatory protein. In fact, anticarcinogenic protease in-
hibitors have been shown to inhibit carcinogen-induced
protease activity, the Boc-Val-Pro-Arg-MCA hydrolyz-
ing activity, in vivo (30), and in vitro (13,28), as well
as radiation-induced c-myc levels in vivo (26).
We are currently attempting to determine whether
the schematic presentation in Figure 2 is actually oc-
curring during the regulation of c-myc expression by
protease inhibitors. Current hypotheses for the mech-
anism of regulation of the c-myc gene are described in
detail elsewhere (23,24). While the exact characteristics
of the regulatory protein hypothesized to be involved
in c-myc gene regulation are unknown, Zajac-Kaye et
al. (41) have described a DNA-binding activity that
binds to the 5' region of the first intron of c-myc; this
binding activity is thought to be intimately involved in
c-myc gene regulation. We are performing experiments
to determine whether alterations in the levels or other
changes in this DNA-binding activity can explain our
observations on protease inhibitors and c-myc gene
expression as they relate to carcinogenesis.
Althoughthemodelsofcarcinogenesis presentedhere
are highly speculative, the anticarcinogenic protease in-
hibitor effects on the suppression of c-myc and c-fos
gene expression and the Boc-Val-Pro-Arg-MCA hydro-
lyzing activity are well documented. It is believed that
the effects of those agents that modify carcinogenesis
on specific genes may lead us to an understanding of
the role these genes play in the carcinogenic process.
Research in our laboratory discussed here is supported by NIH
grants CA-22704, CA-34680, and CA-46496.
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